Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy
Open Access
- 1 February 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (3)
Abstract
Approximately 10% of monogenic diseases are caused by nonsense point mutations that generate premature termination codons (PTCs), resulting in a truncated protein and nonsense-mediated decay of the mutant mRNAs. Here, we demonstrate a mini-dCas13X–mediated RNA adenine base editing (mxABE) strategy to treat nonsense mutation–related monogenic diseases via A-to-G editing in a genetically humanized mouse model of Duchenne muscular dystrophy (DMD). Initially, we identified a nonsense point mutation (c.4174C>T, p.Gln1392*) in the DMD gene of a patient and validated its pathogenicity in humanized mice. In this model, mxABE packaged in a single adeno-associated virus (AAV) reached A-to-G editing rates up to 84% in vivo, at least 20-fold greater than rates reported in previous studies using other RNA editing modalities. Furthermore, mxABE restored robust expression of dystrophin protein to over 50% of WT levels by enabling PTC read-through in multiple muscle tissues. Importantly, systemic delivery of mxABE by AAV also rescued dystrophin expression to averages of 37%, 6%, and 54% of WT levels in the diaphragm, tibialis anterior, and heart muscle, respectively, as well as rescued muscle function. Our data strongly suggest that mxABE-based strategies may be a viable new treatment modality for DMD and other monogenic diseases.Keywords
This publication has 22 references indexed in Scilit:
- A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle CellsCell Stem Cell, 2016
- In vivo gene editing in dystrophic mouse muscle and muscle stem cellsScience, 2016
- The importance of genetic diagnosis for Duchenne muscular dystrophyJournal of Medical Genetics, 2016
- The Pathogenesis and Therapy of Muscular DystrophiesAnnual Review of Genomics and Human Genetics, 2015
- Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyDisease Models & Mechanisms, 2015
- Therapeutic suppression of premature termination codons: Mechanisms and clinical considerations (Review)International Journal of Molecular Medicine, 2014
- Adeno-associated viral vectors do not efficiently target muscle satellite cellsMolecular Therapy - Methods & Clinical Development, 2014
- Cutadapt removes adapter sequences from high-throughput sequencing readsEMBnet.Journal, 2011
- Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapyHuman Molecular Genetics, 2006
- The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX miceJournal of the Neurological Sciences, 1986